Brief Report: Tepotinib as a Treatment Option in MET Exon 14 Skipping-Positive Lung Cancers—Investigating Discordance Between ArcherMET and the Oncomine Dx Target Test

Authors: Yoshihiro Miyashita, MD, Yosuke Hirotsu, PhD, Yuki Nagakubo, MS, Hiroaki Kobayashi, MD, Makoto Kawaguchi, MD, Koki Hata, MD, Ryota Saito, MD, Yumiko Kakizaki, MD, Toshiharu Tsutsui, PhD, Toshio Oyama, MD, Masao Omata, MD

Source: JTO Clinical and Research Reports, Vol 5, Iss 6, Pp 100679- (2024)

Subject Terms: Lung cancer, MET, Tepotinib, Oncomine, Archer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324000493; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/02b007faf1354427b6783f95d8c35a84